Update shared on 03 Jun 2026
Fair value Decreased 18%Analysts have lowered their price target on Bio-Techne from $75.25 to $61.42, citing updated assumptions that include slightly lower revenue growth, modestly higher profit margins, and a reduced future P/E multiple.
What's in the News
- Bio-Techne stock rallied about 12% over a recent five day period, adding roughly US$780 million in market value to reach around US$7.5b in market capitalization, according to recent coverage.
- Recent financial results included a revenue decline and softer biotech spending, which earlier triggered a 16.4% share price drop in May and highlighted mixed recent trading performance. Source: recent analyst and market commentary.
- Analyst opinions remain mixed, with many ratings described as buy or moderate buy and some commentary pointing to high valuation, moderate operating performance, and reliance on potential M&A or adjustments to support future growth. Source: aggregated analyst outlook.
- Bio-Techne introduced a streamlined brand structure around three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, grouping legacy brands and products to match how research moves from discovery to clinical diagnostics. Source: company product announcement.
- The company expanded its COMET spatial biology platform with SPYRE Focus Panels, SPYRE Amplification Kits, and updated HORIZON Image Analysis Software. The goal is to support more flexible multiplex assays and deeper tissue analysis in research and preclinical work. Source: company product announcement.
Valuation Changes
- Fair Value: Updated estimate reduced from $75.25 to about $61.42 per share. This reflects a lower implied valuation level for the stock.
- Discount Rate: Adjusted slightly lower from 7.83% to about 7.77%, pointing to a small change in the required return used in the model.
- Revenue Growth: Assumed long term revenue growth trimmed from about 6.81% to about 6.11%, indicating more cautious top line expectations.
- Profit Margin: Target profit margin raised from about 18.96% to about 19.43%, suggesting a modestly stronger earnings profile in the model.
- Future P/E: Assumed future P/E multiple lowered from about 52.1x to about 43.5x, indicating a reduced valuation multiple applied to projected earnings.
Have other thoughts on Bio-Techne?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.